VectorY Therapeutics and Shape Therapeutics Announce Option and License Agreement to Advance Vectorized Antibodies for Neurodegenerative Diseases Using an AAV5-Derived CNS Capsid

businesswire

VectorY Therapeutics and Shape Therapeutics Announce Option and License Agreement to Advance Vectorized Antibodies for Neurodegenerative Diseases Using an AAV5-Derived CNS Capsid – NEWSnet – News… as it used to be

More Press Releases

May 30, 2026

MakerWorld’s First User-Initiated Charity Contest Names Winners, Bringing Global Creators’ Goodwill Directly to Cancer Wards

May 30, 2026

2026 BRICS New Industrial Revolution Partnership Forum Opened in Xiamen

May 30, 2026

12B SPORTS Named Main Sponsor of VR46 Racing Team for the 2026 MotoGP Season

May 30, 2026

VectorY Therapeutics and Shape Therapeutics Announce Option and License Agreement to Advance Vectorized Antibodies for Neurodegenerative Diseases Using an AAV5-Derived CNS Capsid

MakerWorld’s First User-Initiated Charity Contest Names Winners, Bringing Global Creators’ Goodwill Directly to Cancer Wards

2026 BRICS New Industrial Revolution Partnership Forum Opened in Xiamen

12B SPORTS Named Main Sponsor of VR46 Racing Team for the 2026 MotoGP Season

Douglas French Uncovers the True Causes of Financial Manias in Early Speculative Bubbles Increases in the Supply of Money 4th Expanded Edition